BELLEVUE, Wash., Nov. 2, 2021 /PRNewswire/ — Innovega’s robust portfolio of 51 patent cases now includes a new application teaching machine learning software to regulate the settings of extended reality (XR) eyewear driven by performance measurements of the user while wearing the smart glasses. The application also claims telecommunicating these performance data to healthcare professionals.
"The Innovega team is doubling down on its belief in the value of Personalized Extended Reality with our patent application for using psycho-physiological measures captured by the eyewear to change the settings of the eyewear," shared Dr. Jerome Legerton, Innovega Co-Founder and lead inventor. "XR eyewear have great potential for monitoring health conditions including vision and visual performance, hearing, cognitive function, and psychological status. This patent application provides machine learning algorithms for regulating the settings of the XR eyewear for the vision and hearing output, and for visual, cognitive and psychological therapy by use of measured performance by the user."
The patent application also includes telemedicine systems for communication of changes in vision, hearing, cognition, and psychological measures to respective healthcare professionals. The real-time updates may be particularly useful to monitor patients suffering from progressive conditions like diabetic retinopathy, age-related macular degeneration, hearing loss and cognitive decline as well as managing some psychological conditions.
Innovega CEO and Co-Founder Steve Willey added, "The Intelligent Extended Reality Eyewear patent application is expected to provide Innovega with broad licensing opportunities to complement our smart contact lens technology and our XR hardware, gaze tracking, display technology and methods of fitting XR eyewear. We are now strengthening our position in smart glasses software with five patent cases directed toward software."
Innovega’s 51 patent cases consist of 35 U.S. cases, including 14 issued patents; and 16 international cases, including nine issued patents protecting its iOptik® smart contact lenses and eMacula® display system.
Innovega Inc. is developing stylish, lightweight, wearable displays that feature a high-resolution, panoramic-field-of-view system for medical, consumer, and industrial application. The Company is first licensing its technology into the $74 billion global vision care market with an initial focus on image enhancement for the visually impaired. Its transformative patented platform, eMacula®, combines eyewear and iOptik® high-resolution smart contact lenses to deliver broad application in medicine, augmented reality, and virtual reality. The Company has been supported by the Defense Advanced Research Projects Agency (DARPA), National Eye Institute of National Institutes of Health and National Science Foundation; and received investments from strategic partners.
Innovega is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from Innovega: https://www.seedinvest.com/innovega/.
Steve Willey, CEO
SOURCE Innovega Inc.